Enzo Biochem, Inc. (0IHV.L)
- GlobeNewswire
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5 million improved year-over-year by 14%. During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy mark
- GlobeNewswire
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Meeting Proposals Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D. to the Company’s Board of Directors to hold office for a term ending a
- GlobeNewswire
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023. First Quarter Highlights The Company's Life Sciences division's first quarter revenue improved year-over-year by 10% driven by increased demand in multiple product areas, and stability in our multi-pronged channel to market approach. The Life Sciences division's first quarter gross margin was 44.3%, which impro
